Last reviewed 2026-04-23 · How we verify

HGP0816

HGP0816 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein.

HGP0816 is a selective androgen receptor degrader (SARD) that binds to and promotes degradation of the androgen receptor protein. Used for Castration-resistant prostate cancer (CRPC).

At a glance

Mechanism of action

HGP0816 works by binding to the androgen receptor and recruiting it for proteasomal degradation, thereby eliminating both the protein and its transcriptional activity. This mechanism differs from traditional androgen receptor antagonists by completely removing the receptor rather than simply blocking its function, potentially overcoming resistance mechanisms seen with conventional anti-androgens.

Approved indications

• Castration-resistant prostate cancer (CRPC)

Common side effects

• Fatigue
• Nausea
• Diarrhea
• Rash

Key clinical trials

• Pharmacokinetics of HCP1305 and Co-administration of HCP0605, HGP0816 in Healthy Male Volunteers (PHASE1)
• Pharmacokinetics and Safety of HCP1105 and Co-administration of HGP0918, HGP0816 in Healthy Male Volunteers (PHASE1)
• Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers (PHASE1)
• Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia (PHASE3)
• Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia (PHASE3)
• Evaluating a Pharmacokinetic Drug Interaction Between HGP0918 and HGP0816 (PHASE1)
• Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.